NovaBridge Biosciences (NBP) Cash Flow Statement
NovaBridge Biosciences (NBP) generated -$20.6M of operating cash flow over the twelve months to 2026-06-30, spent $7000 on capital expenditure and had free cash flow of -$20.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NBPNovaBridge BiosciencesFollow NBP — free
—
Price chart with a free account
- Market cap
- 365.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Apr, in 163 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -124.7 | 66.4 | -152.7 | -72.7 | -52.7 | -20.6 | -20.6 | |
| Capital expenditure | 1.8 | 1.2 | 4.7 | 0.2 | 0.0 | 0.0 | -0.0 | |
| Free cash flow | -126.4 | 65.2 | -157.4 | -72.9 | -52.7 | -20.6 | -20.6 | |
| Stock-based compensation | 52.7 | 75.6 | 95.5 | 10.2 | -1.9 | 6.0 | — |
USD millions · SEC XBRL
NovaBridge Biosciences — questions
- What is NovaBridge Biosciences's operating cash flow?
- -$20.6M over the twelve months to 2026-06-30.
- How much does NovaBridge Biosciences spend on capital expenditure?
- $7000 over the twelve months to 2026-06-30.
- What is NovaBridge Biosciences's free cash flow?
- -$20.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from NovaBridge Biosciences's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.